Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 12/20 | 1.00 |
| ▸ | MAOA | P21397 | 2/20 | 0.65 |
| ▸ | MAOB | P27338 | 2/20 | 0.65 |
| ▸ | VCP | P55072 | 2/20 | 0.64 |
| ▸ | TLR4 | O00206 | 3/20 | 0.57 |
| ▸ | TLR2 | O60603 | 3/20 | 0.57 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | ABL2 | P42684 | 1/20 | 0.51 |
| ▸ | TERT | O14746 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1027331 | 1.00 | FBP1 (1.00) | FBP1MAOAMAOBVCPTLR4 | |
| SCHEMBL30995730 | 1.00 | FBP1 (1.00) | FBP1MAOAMAOBVCPTLR4 | |
| SCHEMBL7412213 | 0.80 | FBP1 (0.67) | FBP1VCPABL1EGFRABL2 | |
| SCHEMBL5211010 | 0.79 | FBP1 (0.85) | FBP1MAOAMAOBVCPTLR4 | |
| SCHEMBL13622504 | 0.79 | NFE2L2 (0.79) | FBP1MAOBVCP | |
| SCHEMBL12720865 | 0.78 | FBP1 (1.00) | FBP1MAOAMAOBVCPTLR4 | |
| SCHEMBL527534 | 0.78 | FBP1 (1.00) | FBP1MAOAMAOBVCPTLR4 | |
| SCHEMBL2073418 | 0.78 | FBP1 (1.00) | FBP1MAOAMAOBVCPTLR4 | |
| SCHEMBL1937312 | 0.78 | FBP1 (1.00) | FBP1MAOAMAOBVCPTLR4 | |
| SCHEMBL8625803 | 0.78 | FBP1 (1.00) | FBP1MAOBVCPTLR4TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106117113-B | Polysubstituted carbazole, derivative and its synthetic method | 湘潭大学 | 2019-08-16 | — | — | CN | claimed |
| CN-106117113-A | Polysubstituted carbazole, derivant and synthetic method thereof | 湘潭大学 | 2016-11-16 | — | — | CN | claimed |
| US-12612411-B1 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | INSTITUT PASTEUR (FR) | 2026-04-28 | — | — | US | disclosed |
| US-12576164-B2 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | INSTITUT PASTEUR (FR) | 2026-03-17 | — | — | US | disclosed |
| EP-3964501-B1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | PASTEUR INSTITUT (FR) | 2024-09-04 | — | — | EP | disclosed |
| US-20240197923-A1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | INSTITUT PASTEUR (FR) | 2024-06-20 | — | — | US | disclosed |
| US-11938199-B2 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | INSTITUT PASTEUR (FR) | 2024-03-26 | — | — | US | disclosed |
| EP-3964501-A1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | INSTITUT PASTEUR (FR) | 2022-03-09 | — | — | EP | disclosed |
| EP-3615516-B1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | PASTEUR INSTITUT (FR) | 2021-11-17 | — | — | EP | disclosed |
| US-20200129644-A1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | INSTITUT PASTEUR (FR) | 2020-04-30 | — | — | US | disclosed |
| EP-3615516-A1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | Institut Pasteur (FR) | 2020-03-04 | — | — | EP | disclosed |
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2014-02-13 | — | — | US | disclosed |
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2014-02-13 | — | — | US | disclosed |
| US-8513235-B2 | Homocysteine synthase inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-20 | — | — | US | disclosed |
| EP-2486925-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-08-15 | — | — | EP | disclosed |
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-08-02 | — | — | US | disclosed |
| US-8008508-B2 | Organocatalyst | NATIONAL TAIWAN NORMAL UNIVERSITY (TW) | 2011-08-30 | — | — | US | disclosed |
| US-20110040104-A1 | ORGANOCATALYST | NATIONAL TAIWAN NORMAL UNIVERSITY (TW) | 2011-02-17 | — | — | US | disclosed |
| US-20110034440-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2275404-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11938199-B2 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | NISCH, HLCS, CYP3A5 | FBP1 1893/4885MAOA 2127/4885MAOB 892/4885 |
| US-20200129644-A1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | NISCH, HLCS, CYP3A5 | FBP1 1893/4885MAOA 2127/4885MAOB 892/4885 |
| US-12576164-B2 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | LUC7L2, HLCS, LANCL1 | FBP1 1407/4885MAOA 868/4885MAOB 899/4885 |
| US-20110040104-A1 | ORGANOCATALYST | C1S, C5, H1-0 | FBP1 2022/4885MAOA 858/4885MAOB 1001/4885 |
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | FABP7, TIMP3, MMP11 | FBP1 3695/4885MAOA 1427/4885MAOB 1057/4885 |
| US-12612411-B1 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | LUC7L2, MRPL21, CRY1 | FBP1 794/4885MAOA 1257/4885MAOB 1063/4885 |
| US-20110034440-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | BHMT, CBS, BHMT2 | FBP1 231/4885MAOA 984/4885MAOB 546/4885 |
| US-20240197923-A1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | NISCH, HLCS, CYP3A5 | FBP1 1893/4885MAOA 2127/4885MAOB 892/4885 |
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | CYP17A1, CYP21A2, HSD17B1 | FBP1 2302/4885MAOA 354/4885MAOB 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.